Literature DB >> 16144955

Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients.

Carmen Infante-Duarte1, Alexandra Weber, Jörn Krätzschmar, Timour Prozorovski, Susan Pikol, Isabell Hamann, Judith Bellmann-Strobl, Orhan Aktas, Jan Dörr, Jens Wuerfel, Claus-Steffen Stürzebecher, Frauke Zipp.   

Abstract

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) characterized by enormous variability in its clinical presentation and course, and for which clear diagnostic parameters are lacking. Here we performed an RNA screen in peripheral mononuclear cells from relapsing-remitting (RR) and primary progressive (PP) MS patients compared with healthy donors (HD) that indicated, among other findings, a role for the chemokine receptor CX3CR1 as a diagnostic marker. Gene expression and flow cytometric analyses demonstrated a significantly lower expression of CX3CR1 in MS patients compared with healthy individuals. The subpopulation of cells responsible for causing this reduced expression of CX3CR1 consisted exclusively of natural killer (NK) cells. Importantly, we found a correlation between disease activity and frequency of CX3CR1-positive NK cells in RRMS patients. These findings emphasize the role of NK cells in the development and course of MS and provide evidence for CX3CR1 expression as a marker for MS patients and disease activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16144955     DOI: 10.1096/fj.05-3832fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  27 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

Review 2.  Natural killer cells and their receptors in multiple sclerosis.

Authors:  Gurman Kaur; John Trowsdale; Lars Fugger
Journal:  Brain       Date:  2012-06-25       Impact factor: 13.501

Review 3.  The role of natural killer cells in curbing neuroinflammation.

Authors:  Benjamin M Segal
Journal:  J Neuroimmunol       Date:  2007-09-29       Impact factor: 3.478

Review 4.  NK cell trafficking in health and autoimmunity:a comprehensive review.

Authors:  Hui Peng; Zhigang Tian
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

5.  Analyses of phenotypic and functional characteristics of CX3CR1-expressing natural killer cells.

Authors:  Isabell Hamann; Nadine Unterwalder; Astrid E Cardona; Christian Meisel; Frauke Zipp; Richard M Ransohoff; Carmen Infante-Duarte
Journal:  Immunology       Date:  2011-02-14       Impact factor: 7.397

6.  CX3CR1-dependent recruitment of mature NK cells into the central nervous system contributes to control autoimmune neuroinflammation.

Authors:  Laura Hertwig; Isabell Hamann; Silvina Romero-Suarez; Jason M Millward; Rebekka Pietrek; Coralie Chanvillard; Hanna Stuis; Karolin Pollok; Richard M Ransohoff; Astrid E Cardona; Carmen Infante-Duarte
Journal:  Eur J Immunol       Date:  2016-07-14       Impact factor: 5.532

Review 7.  Regulatory NK-cell functions in inflammation and autoimmunity.

Authors:  Anna Lünemann; Jan D Lünemann; Christian Münz
Journal:  Mol Med       Date:  2009-05-11       Impact factor: 6.354

Review 8.  Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology.

Authors:  Richard M Ransohoff
Journal:  Immunity       Date:  2009-11-20       Impact factor: 31.745

9.  Zinc-ion binding and cytokine activity regulation pathways predicts outcome in relapsing-remitting multiple sclerosis.

Authors:  A Achiron; M Gurevich; Y Snir; E Segal; M Mandel
Journal:  Clin Exp Immunol       Date:  2007-05-04       Impact factor: 4.330

10.  Altered gene expression and function of peripheral blood natural killer cells in children with autism.

Authors:  Amanda M Enstrom; Lisa Lit; Charity E Onore; Jeff P Gregg; Robin L Hansen; Isaac N Pessah; Irva Hertz-Picciotto; Judy A Van de Water; Frank R Sharp; Paul Ashwood
Journal:  Brain Behav Immun       Date:  2008-08-14       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.